FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More

FDA Approves First Immunotherapy-Companion Diagnostic Combo for Lung Cancer

On the heels of the U.S. Food and Drug Administration’s approval of a combination of immune checkpoint inhibitors for unresectable and metastatic melanoma comes yet another immunotherapy approval. This time …

Read More